
SECuRE trial update: First patient treated in the Phase II Cohort Expansion
HIGHLIGHTS The first of the planned 24 participants in the Cohort Expansion Phase (Phase II) of theSECuRE trial has been treated with their first dose of 8 GBq of 67Cu-SAR-bisPSMA.This follows the re